ABSTRACT
We addressed the effect of post-transplant lymphoproliferative disorder (PTLD) treatment with rituximab monotherapy or CHOP-based chemotherapy (+/- rituximab) after upfront immunosuppression reduction (IR) on renal graft function in a longitudinal analysis of 58 renal transplant recipients with PTLD and 610 renal transplant controls. Changes in the estimated glomerular filtration rate over time were calculated from a total of 6933 creatinine measurements over a period of >1 year using a linear mixed model with random and fixed effects. Renal graft function significantly improved with treatment of PTLD, especially in the chemotherapy subgroup. Patients treated with IR+chemotherapy +/- rituximab had a noninferior graft function compared with untreated controls suggesting that the negative impact of IR on the renal graft function can be fully compensated by the immunosuppressive effect of CHOP. The immunosuppressive effect of single agent rituximab may partially compensate the negative impact of IR on the graft function. Thus, it is possible to reduce immunosuppression when using chemotherapy to treat PTLD.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Graft Survival , Immunosuppressive Agents/administration & dosage , Kidney Transplantation/adverse effects , Lymphoproliferative Disorders/drug therapy , Adult , Antibodies, Monoclonal, Murine-Derived , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Female , Humans , Lymphoproliferative Disorders/etiology , Male , Middle Aged , Prednisone/administration & dosage , Prospective Studies , Risk Factors , Rituximab , Vincristine/administration & dosageABSTRACT
Fusarium infections are associated with high mortality after allogeneic stem cell transplantation. We report on successful treatment of a disseminated cutaneous Fusarium proliferatum infection using liposomal amphotericin B and terbinafine. In vitro susceptibility tests of antifungal drugs suggest that terbinafine is a potent additional antifungal drug for disseminated cutaneous fusariosis.
Subject(s)
Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Dermatomycoses/drug therapy , Naphthalenes/therapeutic use , Stem Cell Transplantation/adverse effects , Transplantation, Homologous/adverse effects , Dermatomycoses/microbiology , Drug Therapy, Combination , Female , Fusarium/drug effects , Humans , Middle Aged , Neutropenia/complications , Salvage Therapy , Terbinafine , Treatment OutcomeABSTRACT
BACKGROUND: Anthracyclines are potent chemotherapeutics burdened by their cardiotoxicity. So far no marker to detect early cardiac damage exists. We tested the ability of magnetic resonance imaging (MRI) to show early changes in myocardial signal and cardiac function after anthracycline therapy. METHODS: Twenty-two patients with normal cardiac function were investigated by MRI before and 3 and 28 days after anthracycline chemotherapy. Contrast enhanced fast spin echo images were obtained to characterize myocardial enhancement. Left ventricular ejection fraction was measured by MRI in contiguous short-axis planes. RESULTS: All patients remained clinically stable. Ejection fraction decreased from 67.8% +/- 1.4% to 58.9% +/- 1.9% after 28 days (P < .05). The relative myocardial contrast enhancement increased from 3.8 +/- 0.4 to 6.9 +/- 1.1 (P < .01). An increase of the enhancement of >5 on day 3 compared with baseline predicted a significant loss of ejection fraction at 28 days (67.5% +/- 2.8% to 51.4% +/- 5.6%, mean difference 16.1% +/- 6.6%; P < .05), whereas an increase of +5 was not associated with a significant loss of ejection fraction (67.6% +/- 1.7% to 62.5% +/- 1.4%, mean difference 4.1% +/- 2.6%; P not significant). CONCLUSIONS: MRI detects early changes in myocardial contrast and slightly deteriorating cardiac function in patients receiving anthracyclines. Larger patient cohorts and longer follow-up are needed to evaluate MRI as a predictor for anthracycline cardiotoxicity.
Subject(s)
Antibiotics, Antineoplastic/adverse effects , Myocardium/pathology , Ventricular Function, Left/drug effects , Adolescent , Adult , Aged , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Pilot ProjectsABSTRACT
Mediastinal clear cell lymphoma (MCCL) is regarded as a distinct subtype of Non-Hodgkin's-lymphoma. We have analyzed gene rearrangements of eight cases of newly diagnosed MCCL in order to verify their alignment to the B-cell lineage as suggested by immunotyping. The lymphoma cells shared a common immunophenotype which consisted of CD10-, CD19+, CD20+, and CD21-. Rearrangements of the heavy chain of the immunoglobulin gene were found in all eight cases studied. In contrast, the beta chain of the T-cell antigen receptor gene was not rearranged. No rearrangements of the kappa light chain gene were detected. There was no evidence for a t(14;18) or a t(8;14). In conclusion, MCCL seems to be a B-cell derived tumor, which is distinct from other known lymphomas both by its immunophenotype and genotype.
